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Background: The management of patients with high-grade non muscle invasive bladder cancer (NMIBC) brings
diagnostic and therapeutic challenges. In the current study, we sought to study the natural history of progression
to "secondary" muscle-invasive bladder cancer (MIBC)-cancer that developed during follow up of patients
presenting with non-muscle invasive bladder cancer (NMIBC).
Methods: Between 1998 and 2008, 760 patients were treated for bladder cancer. Primary MIBC (>=T2) tumors
(present upon presentation) were diagnosed in 114 patients. All patients with high-grade NMIBC were treated with
intravesical BCG. Mean follow-up was 44 months.
Results: Forty patients (6.1%) developed secondary MIBC after a mean period of 21 months from initial diagnosis
of bladder cancer. The 2- and 5-year disease-specific survival rates were better for patients with secondary MIBC
(90% and 56% compared to 69% and 42% for patients with primary disease, p=0.03). The Kaplan-Meier curves of
the two groups were parallel but displaced by approximately 2 years.
Conclusion: In the current series, MIBC progression occurred among initially presenting patients with NMIBC in
6.1%. In most patients, the initial diagnosis of NMIBC is correct and muscle invasion occurs after a mean period of
about 2 years. This supports a non-radical approach in patients with high-grade T1, Ta or Tis. Meticulous follow-up
with liberal biopsy of any suspicious lesion may provide early diagnosis of invasive disease.
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Approximately 25% of the urothelial tumors have invaded
the detrusor muscle upon presentation (stage ≥T2), the
rest are NMIBC confined to the bladder mucosa (Ta) or
lamina propria (T1) [1]. High-grade T1 tumors share
many morphologic, genetic and clinical characteristics
with muscle invasive cancer, including varying degrees of
aggressiveness and lethality potential [2-4]. These tumors
tend to recur in 40-70% and progress to muscle invasion
in 10-20% of cases [5,6].
The management of patients with T1 disease is one of
the most challenging issues in urologic oncology. Trans-
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reproduction in any medium, provided the orwith bacillus Calmete-Gúerin is currently advised [7].
Initial response to this therapy is as high as 80%, but over
a ten-year period, only 30% of these patients remain free
of tumor progression or recurrence and up to 50% require
radical cystectomy. Disease-specific mortality rate in these
patients is as high as 30% [4,8].
Although aggressive, radical cystectomy for T1 disease
provides a 5-year disease-specific survival outcome of
80% in reported series [9-11]. Due to morbidity and
disfigurement associated with cystectomy, the timing of
radical cystectomy for high-risk T1 patients remains
controversial.
Approximately 85% of the patients with MIBC
present with muscle-invasion at the first diagnostic
procedure (primary cases), while the rest have a history
of NMIBC (secondary cases). Although patients with
primary and secondary muscle invasive disease are both
offered radical cystectomy the prognosis of thesetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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literature.
Worse prognosis of patients with secondary T2
disease compared to primary T2 was reported [12].
Other authors reported on similar prognosis [13,14]
and even better prognosis for secondary T2 [15]. All
these studies are limited by a small number of patients
and by the inclusion of patients who underwent radical
cystectomy only. Patients with T2 who were treated
non-operatively were not included in any of these
studies.
Outcomes analysis of all patients with primary and
secondary T2-bladder cancer may provide data regarding
the accuracy of TURBT staging and the natural history
of high-grade bladder cancer. To the best of our know-
ledge, this has never been reported.Methods
Patients and treatment
Information was obtained from the Hadassah Hebrew
University Hospital database for 760 patients treated for
bladder cancer between 1998 and 2008. This retrospec-
tive study was approved by the Institutional Review
Board Committee (Institutional Helsinki committee, IRB
number 207–31.10.08).
Diagnoses of primary and secondary bladder cancer
were made using TURBT histological specimens. Patho-
logic staging was performed according to the TNM system
and grading according to the 1973 WHO classification
[16]. All specimens were reviewed by a dedicated uropa-
thologist. Patients with high-grade tumors on initial
diagnosis underwent a second look TURBT 4–6 weeks
following initial resection. When the diagnosis of T1, Tis
or high grade Ta was confirmed an induction course of 6
weekly intravesical instillations of 81 mg Connaught BCG
in 50 cc of normal saline was initiated 10–20 days follow-
ing the TURBT. Six weeks following the last instillation,
urinary cytology and cold-cup bladder biopsies were
obtained. A second induction course was offered to pa-
tients with disease persistence. Responders were given
maintenance therapy (2–3 instillations every 3 months for
one year and 2–3 instillations every 6 months for
additional 2 years). Follow-up protocol included urinary
cytology and cystoscopy every 3 months for 2 years and
every 6 months for an additional 3 years. Upper tract
surveillance (intravenous pyelogram in most instances)
was done annually in patients with high-grade disease.
The diagnosis of MIBC initiated metastatic workup
which included computer tomography of the chest abdo-
men and pelvis. Patients with no evidence of metastases
and reasonable risk for general anesthesia were offered
radical cystectomy. Neoadjuvant chemotherapy was not
used in any patient.Statistical analysis
Disease-free survival for patients with primary MIBC
was calculated from diagnosis. For patients with second-
ary MIBC, survival was calculated twice, from the initial
diagnosis of bladder cancer and from diagnosis of MIBC.
Differences in survival between patients with primary
and secondary MIBC were calculated using Kaplan-
Meier method. Continuous variables were compared
using t-test and categorical variables using Fischer’s
exact test and the chi square test. A p-value <0.05 was
considered statistically significant.
Results
760 patients (mean age 67.5 years, S.D. 12.7 years, 137
females and 623 males) were treated for bladder cancer
at our institution including 476 (62.6%) patients with Ta
tumors, 55 (11.5%) of whom had high-grade carcinoma.
157 patients presented with T1 disease (all with high-
grade cancer) and 114 with primary MIBC disease. Tis
was diagnosed in 137 patients including 13 patients
with pure Tis and 124 patients with concomitant Tis.
Metastatic disease was present in 10 patients upon pre-
sentation, and these patients were excluded from the
analysis.
A total of 40 patients with NMIBC progressed to
MIBC during a mean follow up of 44 months (range=2-
150 months) (secondary MIBC). This group included 30
patients with initial T1, 5 patients with initial pure Tis
and 5 patients with initial Ta disease. Median time to
progression was 12 month (range 3 to 132 month).
Patients with secondary MIBC were compared to 104
patients with primary muscle invasive bladder cancer in
the first TURBT.
Table 1 compares the characteristics of patients with
primary and secondary muscle invasive disease. There
was a trend that patients with secondary MIBC were
younger than patients with initial diagnosis of invasive
disease (69.3 versus 72.7, p=0.08). Radical cystectomy
was performed in 64 patients (61.5%) of the primary
group and 23 patients (57.5%) in the secondary group.
The principle reason for not proceeding with radical
cystectomy were patient preference (36 patients) and
medical comorbidity (21 patients).
Pathological outcomes following radical cystectomy
are summarized in Table 2. The T-stage distribution of
patients with primary and secondary MIBC was signifi-
cantly different (p=0.014), with higher incidinces of pT0
and pT3 disease in patients with secondary MIBC. N0
was more common among patients with secondary dis-
ease (91.3%) compared to primary cases (79.6%) however
this trend was not statistically significance (p=0.33).
Figure 1A presents a Kaplan-Meier analysis of disease
specific survival comparing patients with primary and
secondary MIBC. Survival was calculated from time of
Table 1 Demographic details of patients with primary
and secondary muscle-invasive bladder cancer
Primary Secondary P value
Number 104 40
Mean Age years (S.D.) 72.7 (11.0) 69. 3 (11.3) 0.08
Sex (%)
Male 79 (75.9) 33 (82.5) 0.5
Female 25 (24.1) 7 (17.5)
Number of Patients who
underwent Cystectomy (%)
64 (61.5%) 23 (57.5%) 0.13
Mean Follow-up in
months (range)
40.1 (2–150) 52.6 (5–150) 0.08
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disease specific survival rate were 69% and 42%, respect-
ively for patients with primary muscle-invasive tumors
and 90% and 56%, respectively for patients with second-
ary muscle-invasive tumors (p=0.03). The curve of
patients with secondary T2-disease parallels the curve of
the primary T2-deferred by approximately two years.
Figure 1B presents Kaplan-Meier analysis of the same
groups of patients, but survival was calculated from time
of progression to muscle invasive disease. The two
curves cross each other multiple times. The 2- and 5-
year specific survival rate of patients who progressed
were 81% and 41% respectively (p=0.91).
Analysis of the sub-population that underwent cystec-
tomy also shows that patients with secondary T2 have
better prognosis (2 and 5-year disease free survival of
95% and 66% Vs. 85% and 60% in the secondary and
primary cases respectively), however, without statistical
significance, p=0.45).
Discussion and conclusions
The natural history of high-grade NMIBC is difficult to
predict. Rapid progression to muscle invasion and
metastasis in some patients and indolent, non-progressive
course in others are well known. Factors known to reflect
tumor aggressiveness include high histological grade,
presence of carcinoma-in- situ and tumor recurrenceTable 2 Final pathological staging of patients with
primary and secondary muscle-invasive bladder cancer
who underwent cystectomy
Pathological stage Primary Secondary
pT0 5 (7.8%) 4 (17.4%)
pT1 4 (6.2%) 1 (4.3%)
pT2 25 (39%) 4 (17.4%)
pT3 30 (46.9%) 11 (47.8%)
pT4 0 3 (13%)
N0 51 (79.7%) 21 (91.3%)
N+ 13 (20.3%) 2 (8.7%)following BCG induction [15]. Despite intense research,
clinically useful biological markers for predicting progno-
sis are still absent [7].
The management of high-grade tumors, especially
high-grade T1 cancer is still controversial. Complete
transurethral resection of the tumor, second look and
adjuvant intravesical installation of Bacillus Calmete-
Guerin (BCG) are usually recommended and remain the
standard of care [7]. This policy is supported by
Sylvester et al. who performed meta-analysis of 24
randomized clinical trails including 4863 patients and
showed that induction and maintenance BCG treatment
significantly reduces the risk of superficial bladder can-
cer progression by 27% (from 13.8% to 9.8% p=0.001)
[17]. Moreover, other authors have demonstrated long-
term survival benefit for more aggressive approaches,
specifically early radical cystectomy for the high risk T1
urothelial cancer [2,11,18,19].
In the current study, we have observed that after
median follow-up of 44 months (3.75 years), disease spe-
cific survival of patients with secondary MIBC is not
inferior, rather, superior to the disease specific survival
of patients with primary MIBC (90% vs 69% 2-year
disease specific survival, p=0.03).
Interestingly, the disease specific survival curves of
patients with primary and secondary MIBC shows that
they are parallel, however the curve for the secondary
MIBC cases is displaced by about 2 years. When disease
specific survival of patients with secondary MIBC is
calculated from the date of progression to MIBC, the
survival of patients with primary and secondary MIBC is
similar (Figure 1B).
Several previous comparisons of patients with primary
and secondary MIBC showed contradictory results
[12-15]. Schrier et al., observed poorer outcomes in
patients with secondary MIBC (3 years disease specific
survival of 67% and 37% for patients with primary and
secondary MIBC respectively, p=0.0015) [12]. Both May
et al. [13] and Ferreira et al. [14] showed similar progno-
sis of patients with primary and secondary MIBC. The
five years overall survivals were 46% and 52% for
primary MIBC and 50% and 58% for patients with
secondary T2 in the studies of May et al. and Ferreira
et al. respectively. Vaidya et al. on the other hand, showed
survival benefit for patients with secondary MIBC, with a
2 years disease free survival of 49% in the primary group
and 79% in the secondary invasive group [15].
It is difficult to explain the differences between the
studies. Different population composition can explain
some of discrepancy. In the study by Schrier et al. [12]
for instance, patients with secondary tumors were 5 years
older than patients with primary tumors, while in the
current study and in the study by Vaidya et al., patients
with secondary disease were younger than patients with
Figure 1 Kaplan-Meier survival curves comparing the disease specific survival of patients with primary and secondary T2 bladder
cancer. The numbers represent the numbers of patients at risk. A- Disease specific survival is calculated from the day of bladder cancer.
B- Disease specific survival is calculated from the day of progression to T2 bladder cancer.
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lymph nodes in the work of Schrier et al. was very high
in both groups (30% in the primary and 28% in the
secondary cases) while only 20% of the primary cases
and 8.6% of the secondary cases had positive lymph
nodes in the current study. This suggests that delayed
treatment was given to patients in both groups reported
in the study of Schrier et al. Additionally, there is the
difference in study design between the current and
previous studies. While all previous studies were based
on analysis of cystectomy registries, the current study isbased on analysis of cancer registry and also includes
patients who were not operated.
The significant clinical question behind the figures is
whether a patient diagnosed with high-grade NMIBC
and later progresses to MIBC misses the opportunity to
be cured by early radical cystectomy due to metastatic
spread.
The results presented here are encouraging and
support the policy of conservative treatment with strict
follow up strategy for several reasons: (i) They show that
the initial diagnosis of T1 bladder cancer is correct in
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Muscle invasion (if it occurs) is a later event. (ii) Even if
progression to T2 occurs, many patients can still be
salvaged by delayed cystectomy (or by other treatments),
and their prognosis is not compromised compared to
patients with primary T2 (iii) The lead time between
stage T1 and stage T2 is about 2 years. Meticulous
follow up during this period and a liberal use of bladder
biopsies of any suspicious lesion can potentially diagnose
muscle invasion early.
The current study is limited by being retrospective.
Answering the same question in a prospective study
however, requires randomizing patients with high-grade
NMIBC to early and late cystectomy groups. This design
seems highly unacceptable by most patients.
In conclusion, according to the results, in most cases
the initial diagnosis of T1 disease is accurate and progres-
sion occurs later on. Patients with high-grade NMIBC are
properly managed by intra-vesical instillation of BCG and
by meticulous follow-up. The time interval between the
diagnosis of NMIBC and muscle invasion is about two
years.
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